|
HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
information and resources from the National Cancer Institute
NCI Thesaurus | HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, -A2 and -B35 restricted survivin peptides/Montanide ISA-51 may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. NCI Thesaurus | HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, -A2 and -B35 restricted survivin peptides/Montanide ISA-51 may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens.
|
|
|
|
|
|
HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
-->
|
